In DLBCL patients, TET2 and CREBBP mutations are mutually exclusive, suggesting that TET2 and CREBBP cooperate to regulate cell differentiation and cell-cycle exit and to prevent lymphomagenesis in GC B-cells [61]. Here, CREBBP is linked to diffuse large B-cell lymphoma.